Overview

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:
0

Participant gender:
All

Summary

This is an extension study of ABT-806 for subjects with advanced solid tumors.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Criteria

Inclusion Criteria:

- Subject has completed a prior study utilizing ABT-806 or 111ln ABT-806 (ABT 806i) and
the Investigator believes that continued treatment with ABT-806 is in the best
interest of the subject.

- Women of childbearing potential and men must agree to use adequate contraception (one
of the following listed below) prior to study entry, for the duration of study
participation and for a period of 3 months. Female subjects considered not of
childbearing potential must be documented as being surgically sterile or
post-menopausal for at least 1 year.

- Subject is capable of understanding and complying with parameters as outlined in the
protocol and the subject or the subject's legal acceptable representative is able to
sign informed consent, approved by an Institutional Review Board (IRB) prior to the
initiation of any or study-specific procedures.

Exclusion Criteria:

- Subject discontinued ABT-806 or111ln ABT-806 (ABT-806i) administration before
completing the prior study (due to disease progression, toxicity, withdrawn consent,
other).

- Subject has any medical condition which in the opinion of the investigator places the
subject at an unacceptably high risk for toxicities.

- Subject is a lactating or pregnant female.